LumiThera_FDA
November 5, 2024

FDA Approves Lumithera’s Photobiomodulation Device for Dry AMD

Lumithera’s Valeda becomes the first FDA-approved treatment for vision loss caused by dry AMD Dry AMD sufferers in the United…

popular posts
Article 1 Day 1_ ARVO
May 6, 2025

Inspiring Award Lectures at ARVO 2025 Highlight Decades of Visionary Work

Article 2 Day 5_ ARVO
May 9, 2025

The Next-Gen Arsenal of Genomic Tools for IRDs and Other Eye Diseases Lighting Up ARVO 2025

Thiết kế chưa có tên (15)
May 13, 2025

Aflibercept 8mg Has Been Available for Over a Year. Here’s What nAMD Experts Are Saying About Early Experiences. 

Article 2 Day 4_ARVO
May 8, 2025

Beyond the Genetic Code at ARVO 2025: Breakthrough Approaches to Retinal Repair

latest posts
The Potential for Better and Faster Drying with Longer Treatment Intervals Experts share how aflibercept 8 mg could reshape clinical practice (1)
May 13, 2025

The Potential for Better and Faster Drying with Longer Treatment Intervals

Thiết kế chưa có tên (15)
May 13, 2025

Aflibercept 8mg Has Been Available for Over a Year. Here’s What nAMD Experts Are Saying About Early Experiences. 

Article 2 Day 5_ ARVO
May 9, 2025

The Next-Gen Arsenal of Genomic Tools for IRDs and Other Eye Diseases Lighting Up ARVO 2025

Article 2 Day 4_ARVO
May 8, 2025

Beyond the Genetic Code at ARVO 2025: Breakthrough Approaches to Retinal Repair

Web Day 3
May 7, 2025

ARVO 2025 Day 3: Genetics Deep Dive, Adaptive Optics and Award-Winning Regenerative RP Tech

Article_1_Day_3_ARVO
May 7, 2025

Seeing the Unseen: Adaptive Optics Enters the Clinical Arena at ARVO 2025

Article_2_Day_3_ARVO
May 7, 2025

From Variants to Function: Advanced Research in Genetic Interpretation at ARVO 2025

Article 1 Day 1_ ARVO
May 6, 2025

Inspiring Award Lectures at ARVO 2025 Highlight Decades of Visionary Work

Discover our fascinating content at issuu

explore